Cardiovascular medications frequently lead the polypharmacy category, often contributing to adverse clinical outcomes, and the most vulnerable among us are often prescribed the most complex regimens.

BMI = body mass index; CVD = cardiovascular disease; DM = diabetes mellitus; HDL = high-density lipoprotein; IFN = interferon; NET = neuroendocrine tumor; SLE = systemic lupus erythematosus. The high ...

Secondary prevention medications for cardiovascular diseases (CVD) are underused globally and additional strategies to increase their use are needed to improve CVD management and reduce premature ...

A lower treatment threshold of ≥130/80 mm Hg was associated with reduced postpartum emergency department (ED) visits for a hypertensive disorder of pregnancy (HDOP), according to a study published in ...

Disparities in life expectancy, driven by race, geography, socioeconomic status and systemic inequities, have widened alarmingly – from a 12.6-year gap in 2000 to a staggering 20.4 years by 2021 in ...

Among patients with takotsubo syndrome (TTS), beta-blocker therapy was associated with lower follow-up mortality but not lower TTS recurrence, according to a study published Feb. 5 in JACC: Heart ...

Patients with a history of cardiovascular disease, compared with those without, had a higher incidence of sudden cardiac death (SCD), according to a study of 5.5 million Danish citizens in 2010, ...

Days alive out of health care and hospitalization (DAoH), a novel measure of outcomes in children undergoing cardiovascular surgery, offers advantages over the traditional outcome measure of days ...

In this week’s View, Dr. Eagle looks at cardiac rehabilitation for people with heart failure. He then discusses managing cardiovascular (CV) disease in cancer survivors who have completed cancer ...

Secondary prevention medications for cardiovascular diseases are underused globally and additional strategies to increase their use are needed to improve management and reduce premature mortality ...

In this episode, Drs. Joseph Marine and Rajeev Pathak dive into the ARREST-AF trial and its implications for ablation outcomes in atrial fibrillation (AFib) patients. Listen as they explore the key ...

Pulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S.